AstraZeneca (AZN.US) reslizumab new indication proposed for priority review.

Zhitong Finance APP has learned that on October 12, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration showed that a new indication for AstraZeneca's (AZN.US) rilzabrutinib injection is proposed to be included in priority review, applicable for reducing proteinuria levels in adult patients with primary IgA nephropathy (IgAN). Rilzabrutinib is a blockbuster-level product under AstraZeneca, with global sales of US$4.718 billion in 2025 (YOY +20.23%).